Back to search

Peptide record

TPDB09900

Antibacterial Antifungal Hemolysis Toxicity standard
22 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09900
Antibacterial Antifungal Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia AFP-GFuse Antifungipept CAFPdb APD_complete PD_Hemolysis ToxinPred 3.0
standard
No
A 22-aa standard natural multi-activity (Antibacterial, Antifungal, Hemolysis, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
FFRNLWKGAKAAFRAGHAAWRA
Physicochemical Analysis
C120H174N38O24
DCEQIMPSTYV
A
2532.94
12.71
6
0
13
+5
-3.03
-0.264
49.55
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
11000
434.28
1
Residue Composition
number
7
A
3
R
1
N
0
D
0
C
0
E
0
Q
2
G
1
H
0
I
1
L
2
K
0
M
3
F
0
P
0
S
0
T
2
W
0
Y
0
V
Amino Acid Distribution
A: 7 R: 3 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 1 I: 0 L: 1 K: 2 M: 0 F: 3 P: 0 S: 0 T: 0 W: 2 Y: 0 V: 0
Chemical Descriptors
22
C120H174N38O24
2532.94
12.71
+5
-3.03
-0.264
Evidence Records 19 records
Evidence 1 Activity

Activity

MIC
Antibacterial
6.25 ug/mL

Target

Escherichia coli ATCC 25922

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against Gram- E. coli ATCC 25922 (MIC 6.25 ug/mL), P. aeruginosa ATCC10662 (MIC 50 ug/mL), A. baumannii clinical isolate (MIC 6.25 ug/mL),
Evidence 2 Activity

Activity

MIC
Antibacterial
50 ug/mL

Target

Pseudomonas aeruginosa ATCC10662

Source & Reference

dbAMP DRAMP

Other

Active against Gram- E. coli ATCC 25922 (MIC 6.25 ug/mL), P. aeruginosa ATCC10662 (MIC 50 ug/mL), A. baumannii clinical isolate (MIC 6.25 ug/mL), Gram+ S. aureus ATCC 25923 or MRSA (MIC
Evidence 3 Activity

Activity

MIC
Antibacterial
6.25 ug/mL

Target

A. baumannii clinical isolate

Source & Reference

dbAMP DRAMP

Other

gainst Gram- E. coli ATCC 25922 (MIC 6.25 ug/mL), P. aeruginosa ATCC10662 (MIC 50 ug/mL), A. baumannii clinical isolate (MIC 6.25 ug/mL), Gram+ S. aureus ATCC 25923 or MRSA (MIC 3.1 ug/mL), S. epidermidis ATCC 1435 (MIC 1.6 ug
Evidence 4 Activity

Activity

MIC
Antibacterial
3.1 ug/mL

Target

Staphylococcus aureus ATCC 25923 or MRSA

Source & Reference

dbAMP DRAMP

Other

eruginosa ATCC10662 (MIC 50 ug/mL), A. baumannii clinical isolate (MIC 6.25 ug/mL), Gram+ S. aureus ATCC 25923 or MRSA (MIC 3.1 ug/mL), S. epidermidis ATCC 1435 (MIC 1.6 ug/mL), and fungi C. albicans (MIC 6.2 ug/ml), C. trop
Evidence 5 Activity

Activity

MIC
Antibacterial
1.6 ug/mL

Target

Staphylococcus epidermidis ATCC 1435

Source & Reference

dbAMP DRAMP

Other

ii clinical isolate (MIC 6.25 ug/mL), Gram+ S. aureus ATCC 25923 or MRSA (MIC 3.1 ug/mL), S. epidermidis ATCC 1435 (MIC 1.6 ug/mL), and fungi C. albicans (MIC 6.2 ug/ml), C. tropicalis (MIC 6.2 ug/ml). Inactive: C.glabra
Evidence 6 Activity

Activity

MIC
Antibacterial
6.2 µg/mL

Target

Candida albicans

Source & Reference

dbAMP DRAMP

Other

s ATCC 25923 or MRSA (MIC 3.1 ug/mL), S. epidermidis ATCC 1435 (MIC 1.6 ug/mL), and fungi C. albicans (MIC 6.2 ug/ml), C. tropicalis (MIC 6.2 ug/ml). Inactive: C.glabrata clinical isolate (MIC >100 ug/ml). B
Evidence 7 Activity

Activity

MIC
Antibacterial
6.2 µg/mL

Target

C. tropicalis

Source & Reference

dbAMP DRAMP

Other

ug/mL), S. epidermidis ATCC 1435 (MIC 1.6 ug/mL), and fungi C. albicans (MIC 6.2 ug/ml), C. tropicalis (MIC 6.2 ug/ml). Inactive: C.glabrata clinical isolate (MIC >100 ug/ml). Bacterial killing kinetics is si
Evidence 8 Activity

Activity

MIC
Antibacterial
>100 µg/mL

Target

C.glabrata clinical isolate

Source & Reference

dbAMP DRAMP

Other

6 ug/mL), and fungi C. albicans (MIC 6.2 ug/ml), C. tropicalis (MIC 6.2 ug/ml). Inactive: C.glabrata clinical isolate (MIC >100 ug/ml). Bacterial killing kinetics is similar to moronecidin. In addiiton, this peptide inhibite
Evidence 9 Activity

Activity

MIC
Antifungal
6.25 ug/mL

Target

Escherichia coli ATCC 25922

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against Gram- E. coli ATCC 25922 (MIC 6.25 ug/mL), P. aeruginosa ATCC10662 (MIC 50 ug/mL), A. baumannii clinical isolate (MIC 6.25 ug/mL),
Evidence 10 Activity

Activity

MIC
Antifungal
50 ug/mL

Target

Pseudomonas aeruginosa ATCC10662

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against Gram- E. coli ATCC 25922 (MIC 6.25 ug/mL), P. aeruginosa ATCC10662 (MIC 50 ug/mL), A. baumannii clinical isolate (MIC 6.25 ug/mL), Gram+ S. aureus ATCC 25923 or MRSA (MIC
Evidence 11 Activity

Activity

MIC
Antifungal
6.25 ug/mL

Target

A. baumannii clinical isolate

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

gainst Gram- E. coli ATCC 25922 (MIC 6.25 ug/mL), P. aeruginosa ATCC10662 (MIC 50 ug/mL), A. baumannii clinical isolate (MIC 6.25 ug/mL), Gram+ S. aureus ATCC 25923 or MRSA (MIC 3.1 ug/mL), S. epidermidis ATCC 1435 (MIC 1.6 ug
Evidence 12 Activity

Activity

MIC
Antifungal
3.1 ug/mL

Target

Staphylococcus aureus ATCC 25923 or MRSA

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

eruginosa ATCC10662 (MIC 50 ug/mL), A. baumannii clinical isolate (MIC 6.25 ug/mL), Gram+ S. aureus ATCC 25923 or MRSA (MIC 3.1 ug/mL), S. epidermidis ATCC 1435 (MIC 1.6 ug/mL), and fungi C. albicans (MIC 6.2 ug/ml), C. trop
Evidence 13 Activity

Activity

MIC
Antifungal
1.6 ug/mL

Target

Staphylococcus epidermidis ATCC 1435

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

ii clinical isolate (MIC 6.25 ug/mL), Gram+ S. aureus ATCC 25923 or MRSA (MIC 3.1 ug/mL), S. epidermidis ATCC 1435 (MIC 1.6 ug/mL), and fungi C. albicans (MIC 6.2 ug/ml), C. tropicalis (MIC 6.2 ug/ml). Inactive: C.glabra
Evidence 14 Activity

Activity

MIC
Antifungal
6.2 µg/mL

Target

Candida albicans

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

s ATCC 25923 or MRSA (MIC 3.1 ug/mL), S. epidermidis ATCC 1435 (MIC 1.6 ug/mL), and fungi C. albicans (MIC 6.2 ug/ml), C. tropicalis (MIC 6.2 ug/ml). Inactive: C.glabrata clinical isolate (MIC >100 ug/ml). B
Evidence 15 Activity

Activity

MIC
Antifungal
6.2 µg/mL

Target

C. tropicalis

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

ug/mL), S. epidermidis ATCC 1435 (MIC 1.6 ug/mL), and fungi C. albicans (MIC 6.2 ug/ml), C. tropicalis (MIC 6.2 ug/ml). Inactive: C.glabrata clinical isolate (MIC >100 ug/ml). Bacterial killing kinetics is si
Evidence 16 Activity

Activity

MIC
Antifungal
>100 µg/mL

Target

C.glabrata clinical isolate

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

6 ug/mL), and fungi C. albicans (MIC 6.2 ug/ml), C. tropicalis (MIC 6.2 ug/ml). Inactive: C.glabrata clinical isolate (MIC >100 ug/ml). Bacterial killing kinetics is similar to moronecidin. In addiiton, this peptide inhibite
Evidence 17 Activity

Activity

50% Hemolysis
Toxicity
87.5 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 87.5 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Identification and Characterization of Novel Antimicrobial Peptide from Hippocampus comes by In Silico and Experimental Studies. | Mar Biotechnol | 2018
Evidence 18 Activity

Activity

% Hemolysis
Toxicity
50 %
Hemolytic
Hemolytic_activity: [Ref.30039186] 50% hemolysis at 87.5µg/ml,25% hemolysis at 50µg/ml,60% hemolysis at 100µg/ml against human red cells

Target

erythrocytes

Source & Reference

NA
DRAMP
Mar Biotechnol (NY). 2018 Dec 20(6):718-728.
Evidence 19 Hemolysis

Source & Reference

APD_complete PD_Hemolysis
APD_complete PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation.